Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

A new, effective, non-surgical treatment for uterine fibroids can help women with this condition maintain their fertility, an American scientist told the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Wednesday).

30 Jun 2010

International symposium to highlight current and future applications of MR-guided ultrasound

Leading research and clinical experts from around the world are scheduled to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be held October 17 to 20 in the Washington, D.C. area.

From Elekta 29 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy. "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer.

16 Jun 2010

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.

11 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

New research findings from fertility experts from Europe, the Americas, Asia & Australasia

31 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 May 2010

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.

14 May 2010

Merit Medical Systems to acquire BioSphere Medical

Merit Medical Systems, Inc. today announced that it has signed a definitive merger agreement to acquire BioSphere Medical, Inc. in an all cash transaction valued at approximately $96 million, inclusive of all common equity and Series A Preferred preferences.

14 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

Journal of Minimally Invasive Gynecology (JMIG) has published a study in its March/April issue which concluded that establishing a referral relationship with an interventional radiologist for comprehensive uterine myoma (fibroid) treatment supports a trusting, collaborative, long-term, noncompetitive ''win-win'' relationship between the gynecologist and radiologist.

13 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

With over 10 million women in the U.S. suffering from endometrial disorders like abnormal uterine bleeding or uterine fibroids, the 2010 American Institute of Ultrasound Medicine convention will feature specialized programs and product showcases highlighting imaging solutions available to better diagnose these conditions.

26 Mar 2010

Study reveals comparable fertility rates between UFE and surgical myomectomy

Uterine fibroid embolization, a minimally invasive interventional radiology procedure that blocks blood supply to treat painful uterine fibroids, has a comparable fertility rate to myomectomy, the surgical removal of uterine fibroids, for women who want to conceive, according to the first study on the subject released at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

International symposium to highlight current and future applications of MR-guided ultrasound

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

PCA-Rx represents next generation of chelation technology for ASD patients

MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

Merit Medical Systems to acquire BioSphere Medical

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

FDA issues advisory on prostate cancer drugs

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

Noncompetitive ''win-win'' relationship between gynecologist and radiologist benefits patients

StockPreacher.com releases investment report on Repros Therapeutics

Request for lift of full clinical hold on Proellex program

Cook Medical to feature its Goldstein SonoBiopsy Catheter at 2010 AIUM convention

Study reveals comparable fertility rates between UFE and surgical myomectomy

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in